$NVO

Novo Nordisk cuts GLP-1 drug prices 50% to $675/month starting 2027 amid clinical setbacks and competitive pressure from rivals like Eli Lilly.

Novo Nordisk licenses Vivtex's oral drug-delivery technology for obesity and diabetes treatments, with potential $2.1B in milestone payments to develop oral alternatives to injectable biologics.

Novo Nordisk dominates the GLP-1 market with Ozempic and Wegovy, but faces stiff competition from Eli Lilly and disappointing trial results that may limit exceptional long-term returns.

Hims stock down 75% due to Novo Nordisk lawsuit over semaglutide marketing, but analysts see 150% upside potential and record revenue coming.

Novo Nordisk's obesity drug UBT251 achieved 19.7% weight loss in Phase 2 trials for Chinese patients, offsetting recent setbacks from a failed competitor drug trial.

Viking Therapeutics advances obesity drug VK2735 into Phase 3 trials after positive interim results, positioning itself in the competitive weight-loss pharmaceutical market.

Novo Nordisk shares fell 16% after CagriSema obesity drug trial underperformed rival Eli Lilly's tirzepatide. Deutsche Bank downgraded the stock amid competitive concerns.

Veeva Systems targets $6B revenue by 2030, doubling current business. Stock down 35% recently, but specialized platform and customer switching costs support long-term growth outlook.

Viking Therapeutics surged 10.91% after Novo Nordisk's obesity drug failed against Eli Lilly's competitor. Viking's dual injectable/oral candidate VK2735 offers differentiation entering Phase 3 trials.

Novo Nordisk stock drops 15.9% after CagriSema obesity drug fails trial versus competitor tirzepatide, signaling intensifying competition in the GLP-1 market despite Wegovy's strength.

Novo Nordisk's CagriSema underperformed Eli Lilly's tirzepatide in weight-loss trials, delivering 20.2% versus 23.6% weight reduction, triggering stock declines amid intensifying obesity drug competition.

Novo Nordisk's stock fell 16% after CagriSema obesity drug failed to match Eli Lilly's tirzepatide in trial, showing weaker weight loss results and jeopardizing approval timeline.

Novo Nordisk stock down 67% offers entry point for long-term investors. Strong GLP-1 market position, attractive valuation metrics, and growth potential despite upcoming competition.

Novo Nordisk shares plunged 13% after CagriSema obesity drug trial missed non-inferiority target versus Eli Lilly's tirzepatide, threatening competitive positioning.

Viking Therapeutics poised for growth as obesity drug market expands to $100 billion by decade's end. VK2735's Phase 3 success could establish the company as a key competitor.

Oral weight-loss drugs expand the market rather than cannibalizing injectables, attracting new patients. However, Novo Nordisk expects 2026 revenue headwinds from competition and pricing pressures.

Intuitive Surgical posts double-digit growth in 2025 with 12% installed base expansion and 18% surgery increase, unaffected by GLP-1 drug market competition.

GLP-1 therapeutics market projected to grow from $22B in 2025 to $33B by 2030, driven by formulation innovations like oral and extended-release therapies improving accessibility.

Hims & Hers to acquire Eucalyptus for $1.15B, expanding into Australia, UK, and Germany. Deal closes mid-2026, marking major international growth push.

Alzheimer's therapeutics market projected to exceed $6B by 2026 driven by rising disease prevalence and increased pharma investment in disease-modifying treatments.